Pharmacies must: Cease production of compounded semaglutide that duplicates FDA-approved products Dispense compounded medications only when supported by a valid, patient-specific prescription that meets Section 503A criteria Remaining Legal Pathways for Compounded Semaglutide Compounded semaglutide may be prescribed only in rare cases where an FDA-approved product cannot be used, such as a documented allergy to an inactive ingredient
In laboratory settings, it is commonly explored for metabolic regulation, energy balance, appetite signalling, and lipid metabolism pathways
HarrisMartin Publishing
Abstract The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity
In a cardiovascular outcomes trial, semaglutide treatment increased retinopathy complications
Quality and purity vary significantly between suppliers, making third-party testing verification essential
